⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416938 | 1.00 | — | — | |
| SCHEMBL19264470 | 0.79 | — | — | |
| SCHEMBL10243418 | 0.77 | — | — | |
| SCHEMBL10090955 | 0.73 | — | — | |
| SCHEMBL12974438 | 0.73 | — | — | |
| SCHEMBL12974391 | 0.73 | — | — | |
| SCHEMBL2047428 | 0.72 | — | — | |
| SCHEMBL17173288 | 0.71 | — | — | |
| SCHEMBL17173287 | 0.71 | — | — | |
| SCHEMBL19852862 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026948-A1 | POLYOL COMPOSITIONS AND METHODS | ARAMCO PERFORMANCE MATERIALS LLC | 2023-01-26 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210129125-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10207262-B2 | Chromium complex and catalyst therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180071725-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9546160-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160137777-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2016-05-19 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-10 | — | — | US | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |